NEW YORK (GenomeWeb News) - The Center for Molecular Medicine said today that it will offer three cancer tests developed by AviaraDx in an effort to help physicians make more informed decisions in managing oncology patients.
Under the agreement, CMM said it will advise physicians on the value and clinical utility of the AviaraDx tests, and will coordinate sample preparation and shipping. AviaraDx will analyze the tumor samples in its CLIA-certified, CAP-accredited laboratory.
The agreement covers three tests: CancerTYPE ID, which pinpoints a tumor's organ of origin; H/I, which uses a two-gene expression signature as an independent predictor of treatment outcome for breast cancer patients receiving endocrine therapy; and Molecular Grade Index, or MGI, which uses a five-gene signature to discriminate between tumor grades 1 and 3 and to reclassify grade 2 tumors as either grade-1 like or grade 3-like.
CMM said the AviaraDx cancer tests will complement the CellSearch suite of tests from Veridex that it already offers as part of its cancer-management portfolio.
“While the AviaraDx tests will typically be used in the earlier stages of a patient's diagnosis and treatment, the CellSearch System helps physicians more effectively manage patients with more advanced metastatic colorectal, breast and prostate cancer,” CMM said in a statement.